Nucleotide Analogs
Since lamivudine’s licensing in the late nineties, chronic HBV or hepatitis B treatment has been transformed and revolutionized by nucleotide analog introduction, which acts as HBV polymerase inhibitors. And while their efficacy was initially limited by resistance and incomplete response to many people. However, more highly potent variations are available that can reliably suppress the replication of the virus, reduce necroinflammatory activity in your liver, and minimize the potential reversion of fibrosis.
Apart from that, nucleotide analog treatment may prevent hepatocellular carcinoma development. However, after the treatment’s cessation, replication of HBV may relapse in some patients. For this reason, NA treatment remains indefinite, and the goal of any treatment strategies using this medication should be tailoring the regimen based on the individual and the condition.
Nucleotide analogs are typically well-tolerated. Tenofovir and adefovir can potentially cause nephrotoxicity and damage the renal tubular’s cells. However, the risks are low, and any harm that may come from the treatment is usually reversible. Nevertheless, those treated using these medications should regularly be monitored, especially for any conditions associated with renal dysfunction. There have also been reports that tenofovir may cause losses in bone mineral densities and is worth tracking.
